The prevalence of contact sensitization in atopic dermatitis (AD) has been controversial and remains poorly studied in the Chinese population. This retrospective study aimed to assess the prevalence and differences ofin contact sensitization between AD and non-AD patients undergoing patch testing in China. We analyzedanalysed clinical records of 3,487 patients who underwent patch testing from 2018 to 2023,, including 146 AD patients and 33413,341 non-AD patients. Results demonstrated that contact sensitization prevalence was similar in AD and non-AD groups (82.88% vs 84.71%, p=0.55). Common allergens included nickel, methylisothiazolinone, dodecyl gallate, and cobalt chloride hexahydrate in both groups. AD patients showed higher positive reactions to hexahydro-1,3,5-tris-(2-hydroxyethyl) triazine (11.11% vs 5.85%, p<0.01), methyldibromo glutaronitrile (10.27% vs 4.97%, p<0.01), quaternium-15 (7.53% vs 3.68%, p=0.02), ethylenediamine dihydrochloride (3.42% vs 0.72%, p<0.01), propylene glycol (2.86% vs 0.60%, p=0.01), and 2-bromo-2-nitropropane-1,3-diol (2.74% vs 0.78%, p=0.03), compared to non-AD, particularly females. Contact sensitization prevalence increased with age in both groups. This study showed that the prevalence of contact sensitization was comparable between the AD and non-AD groups in China. However, AD patients exhibited heightened sensitivity to formaldehyde releasers and propylene glycol, commonly found in moisturizers.
Patients with hidradenitis suppurativa experience considerable disease burden and reduced health-related quality of life (HRQoL). Diagnostic delays are common and may impede timely treatment initiation, contributing to disease progression. This study utilizes data (2010–2022) from the Scandinavian Registry for hidradenitis suppurativa (HISREG) in adult patients with hidradenitis suppurativa. Here, we report time between first hidradenitis suppurativa-related symptom, general practitioner visit and dermatologist visit; Dermatology Life Quality Index (DLQI) score and most impacted items; and hidradenitis suppurativa treatment patterns in Denmark, Norway and both countries combined. Analysis was stratified by Hurley stage. In both countries combined, considerable gaps (≥10 years) were reported between first hidradenitis suppurativa-related symptom and dermatologist visit, with the greatest delay in Hurley stage III patients (14 years). Mean DLQI scores ranged from 8.6 to 14.6; scores were highest in Hurley stage III patients. The most impacted DLQI items were “Itch/soreness/pain” or “Bothered/embarrassed”. Surgery was more common in Hurley stage III vs I patients (30.1% vs 10.6%); 8.6% of Hurley stage III patients did not receive additional intervention for hidradenitis suppurativa (doctor-determined). In conclusion, HISREG-registered patients experienced substantial delays to dermatologist visits, impaired HRQoL and a paucity of effective treatments. These burdens were particularly pronounced for patients with moderate and severe hidradenitis suppurativa.
Atopic dermatitisis a chronic skin disease that requires long-term monitoring, which can be assessed using Atopic Dermatitis Control Tool (ADCT). Achieving minimal disease activity is also becoming an important issue in the treatment of atopic dermatitis. We aimed to identify which minimal disease sctivity patient-reported outcomes most closely reflect ADCT-defined disease control. We conducted a multicentric, observational retrospective study in patients with moderate-to-severe atopic dermatitis treated with upadacitinib. Outcome measures were collected at different time points (Week 0, 4, 16, 32, 52). Longitudinal changes were assessed with the paired Wilcoxon signedrank test; cross-sectional ADCT–patient-reported outcomes associations were evaluated at each visit using Spearman rank correlation coefficient (ρ). A total of 212 were included. All outcomes improved significantly from Week 4 onwards (all p<0.001). An ADCT score<7 was reached by 84.6% of evaluable patients at Week 4 and 90.1% at Week 52. At each timepoint, ADCT showed the strongest correlation with POEM (ρ range: 0.64–0.64) compared to other minimal disease sctivity patient-reported outcomes. These findings indicate that, among the minimal disease sctivity patient-reported outcomes, POEM most closely reflects the patient’s perception of atopic dermatitis control assessed by ADCT. Larger prospective studies are warranted to confirm these preliminary observations.
